Soleus Capital Amends Pieris Pharma Stake as of Dec 31, 2023

Ticker: PVLA · Form: SC 13G/A · Filed: Feb 2, 2024 · CIK: 1583648

Pieris Pharmaceuticals, Inc. SC 13G/A Filing Summary
FieldDetail
CompanyPieris Pharmaceuticals, Inc. (PVLA)
Form TypeSC 13G/A
Filed DateFeb 2, 2024
Risk Levelmedium
Pages7
Reading Time9 min
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: institutional-ownership, amendment, biotech, investor-update

TL;DR

**Soleus Capital updated its Pieris Pharma holdings, watch for potential shifts in institutional sentiment.**

AI Summary

Soleus Capital Master Fund, L.P. filed an amendment to its Schedule 13G, indicating its ownership of Pieris Pharmaceuticals, Inc. common stock as of December 31, 2023. This filing, an Amendment No. 2, updates previous disclosures, signaling a potential change in their investment stake or reporting status. This matters to investors because Soleus Capital is a significant institutional investor, and changes in their holdings can influence market perception and potentially the stock price of Pieris Pharmaceuticals.

Why It Matters

This filing shows an institutional investor's updated position in Pieris Pharmaceuticals, which can signal their confidence (or lack thereof) in the company's future prospects, potentially impacting other investors' decisions.

Risk Assessment

Risk Level: medium — Changes in institutional ownership can create volatility, especially for smaller biotech companies like Pieris Pharmaceuticals.

Analyst Insight

Investors should monitor subsequent filings from Soleus Capital Master Fund, L.P. to see if their ownership percentage in Pieris Pharmaceuticals, Inc. has significantly changed, as this filing is an amendment and doesn't detail the exact percentage or share count in the provided text.

Key Players & Entities

  • Soleus Capital Master Fund, L.P. (company) — the reporting person and institutional investor
  • PIERIS PHARMACEUTICALS, INC. (company) — the subject company whose stock is being reported
  • Guy Levy (person) — a group member associated with Soleus Capital
  • Soleus Capital Group, LLC (company) — a group member associated with Soleus Capital
  • Soleus Capital, LLC (company) — a group member associated with Soleus Capital
  • December 31, 2023 (date) — the date of the event requiring the filing

FAQ

What type of filing is this document?

This document is an 'AMENDMENT NO. 2 TO SCHEDULE 13G', specifically an SC 13G/A, filed under Rule 13d-1(c) of the Securities Exchange Act of 1934.

Who is the reporting person in this filing?

The reporting person is Soleus Capital Master Fund, L.P., with an IRS Identification No. of 981413657 and incorporated in E9 (Cayman Islands).

What is the subject company whose securities are being reported?

The subject company is PIERIS PHARMACEUTICALS, INC., with a CUSIP Number of 720795103 and a Central Index Key (CIK) of 0001583648.

What is the 'Date of Event Which Requires Filing of this Statement'?

The date of the event which requires the filing of this statement is December 31, 2023.

Which specific rule under the Securities Exchange Act of 1934 is this Schedule 13G filed under?

This Schedule 13G is filed under Rule 13d-1(c) of the Securities Exchange Act of 1934, as indicated by the checked box on the cover page.

Filing Stats: 2,161 words · 9 min read · ~7 pages · Grade level 9.9 · Accepted 2024-02-02 09:59:33

Filing Documents

If this statement is filed pursuant to §§240.13d-1(b)

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J). (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

Ownership

Item 4. Ownership. Reference is made to Items 5 – 11 on the preceding pages of this Schedule 13G. 7

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following .

Ownership of More than Five Percent on Behalf of Another

Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable.

Identification and Classification of the Subsidiary Which

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Not applicable.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group Not applicable.

Certification

Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. 8 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct. Date : February 2, 2024 Soleus Capital Master Fund, L.P. By: Soleus Capital, LLC, its General Partner By: Soleus Capital Group, LLC, its Managing Manager By: /s/ Guy Levy Name: Guy Levy Title: Managing Member Date : February 2, 2024 Soleus Capital, LLC By: Soleus Capital Group, LLC, its Managing Manager By: /s/ Guy Levy Name: Guy Levy Title: Managing Member Date : February 2, 2024 Soleus Capital Group, LLC By: /s/ Guy Levy Name: Guy Levy Title: Managing Member Date : February 2, 2024 /s/ Guy Levy Name: Guy Levy Footnotes: Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) 9 EXHIBIT A JOINT FILING AGREEMENT Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934, as amended. It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy o

View Full Filing

View this SC 13G/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.